Literature DB >> 3411597

Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.

V E Marquez1, M I Lim, S P Treanor, J Plowman, M A Priest, A Markovac, M S Khan, B Kaskar, J S Driscoll.   

Abstract

Cyclopentenylcytosine (CPE-C, 2), a pyrimidine analogue of the fermentation derived carbocyclic nucleoside neplanocin A, has been synthesized from the optically active cyclopentenylamine 3b by two synthetic routes. CPE-C demonstrates significant antitumor activity against both the sensitive and ara-C resistant lines of L1210 leukemia in vivo. Multiple long term survivors are produced in both tumor models. The compound also gives 100% growth inhibition of the solid human A549 lung and MX-1 mammary tumor xenografts grown in athymic mice. Good activity is also observed against a third human tumor xenograft model, metastatic LOX melanoma. CPE-C has significant activity against both DNA and RNA viruses in vitro. Potent activity is observed against HSV-1 (TK+ and TK-), HSV-2, vaccinia, cytomegalovirus, and varicella-zoster virus. Good activity is also found against a strain of influenza virus (Hong Kong flu), vesicular stomatitis virus, Japanese encephalitis virus, and Punta Toro virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411597     DOI: 10.1021/jm00117a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Carbocyclic thymidine analogues for use as potential therapeutic agents.

Authors:  Katherine L Seley-Radtke; Naresh K Sunkara
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-05       Impact factor: 1.381

Review 2.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.

Authors:  D S Zaharko; J A Kelley; J E Tomaszewski; L Hegedus; N R Hartman
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

4.  In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

Authors:  D A Volpe; D L Du; C K Grieshaber; M J Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Historical perspectives in the development of antiviral agents against poxviruses.

Authors:  Erik De Clercq
Journal:  Viruses       Date:  2010-06-14       Impact factor: 5.818

Review 7.  Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues.

Authors:  Mieke Guinan; Caecilie Benckendorff; Mark Smith; Gavin J Miller
Journal:  Molecules       Date:  2020-04-28       Impact factor: 4.411

8.  Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine.

Authors:  E De Clercq; R Bernaerts; Y F Shealy; J A Montgomery
Journal:  Biochem Pharmacol       Date:  1990-01-15       Impact factor: 5.858

9.  Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase.

Authors:  E De Clercq; J Murase; V E Marquez
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

Review 10.  Molecular strategies to inhibit the replication of RNA viruses.

Authors:  Pieter Leyssen; Erik De Clercq; Johan Neyts
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.